VC-backed Phreesia starts trading on the NYSE


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Phreesia, a patient intake management platform, has debuted its IPO after pricing its over 9.2 million shares at $18 per share. The stock began trading July 18, 2019 on the New York Stock Exchange under the ticker symbol “PHR.” J.P. Morgan, Wells Fargo Securities and William Blair are the lead underwriters. Phreesia’s pre-IPO backers included LLR Partners, HLM Venture Partners, Polaris Partners, Ascension Ventures, Echo Health Venture and Blue Cross Blue Shield Venture Partners.

PRESS RELEASE

NEW YORK, July 17, 2019 /PRNewswire/ — Phreesia, Inc. (“Phreesia”), a leading patient intake management platform, today announced the pricing of its initial public offering of 9,288,194 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts, consisting of 7,812,500 shares to be issued and sold by Phreesia (the “Primary Shares”) and 1,475,694 shares to be sold by certain of Phreesia’s existing stockholders

Continue reading “VC-backed Phreesia starts trading on the NYSE”

VC-backed Mirum Pharmaceuticals debuts IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Foster City, California-based Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symbol “MIRM.” Citigroup, Evercore ISI and Guggenheim Securities are the lead underwriters. Mirum’s pre-IPO backers included NEA, Deerfield Management, Frazier Healthcare Partners, Novo Holdings, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.

PRESS RELEASE

FOSTER CITY, Calif., July 17, 2019 /PRNewswire/ — Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and

Continue reading “VC-backed Mirum Pharmaceuticals debuts IPO”

VC-backed Fulcrum Therapeutics goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Cambridge, Massachusetts-based Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has raised $72 million for its IPO after pricing its 4.5 million shares at $16 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symbol “FULC.” Morgan Stanley, BofA Merrill Lynch and SVB Leerink are the lead underwriters. Fulcrum’s pre-IPO backers included Third Rock Ventures and Foresite Capital.

PRESS RELEASE

CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases, today announced the pricing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $72.0 million, before underwriting discounts and commissions and offering

Continue reading “VC-backed Fulcrum Therapeutics goes public”

Pivotal raises $200 mln for IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Pivotal Investment Corporation II, a blank check company, has raised $200 million for its IPO after pricing its 20 million shares at $10 per share. The stock began trading July 12, 2019 on the New York Stock Exchange under the ticker symbol “PIC.U.” Cantor Fitzgerald and BTIG LLC are the underwriters. This past May, Pivotal merged with KLDiscovery, a provider of electronic discovery and information governance services to Fortune 500 companies and top law firm. KLD is backed by Carlyle and Revolution Growth.

PRESS RELEASE

New York, NY, July 11, 2019 – Pivotal Investment Corporation II (NYSE: PIC.U) (the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will commence trading July 12, 2019 on the NYSE under the symbol “PIC.U”. Each unit consists of one share of the Company’s Class A common

Continue reading “Pivotal raises $200 mln for IPO”

Thoma Bravo-backed Dynatrace files to go public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Waltham, Massachusetts-based Dynatrace, a provider of software intelligence, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Dynatrace will trade the stock on the New York Stock Exchange under the ticker symbol “DT.” Goldman Sachs, JP Morgan Securities LLC and Citigroup Global Markets are the lead underwriters. Dynatrace is a portfolio company of Thoma Bravo.

PRESS RELEASE

Waltham, Mass., July 5, 2019. – Dynatrace Holdings LLC, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Dynatrace has applied to list its common stock on the New York Stock

Continue reading “Thoma Bravo-backed Dynatrace files to go public”

ProSight Global files to go public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Morristown, New Jersey-based ProSight Global, a provider of specialty insurance, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading the stock on the New York Stock Exchange under the ticker symbol “PROS.” Goldman Sachs and Barclays are the lead underwriters. ProSight is backed by Goldman Sachs and TPG.

PRESS RELEASE

MORRISTOWN, N.J., July 1, 2019 /PRNewswire/ — ProSight Global, Inc., a leader in differentiated specialty insurance, today announced that on June 28, 2019 it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. ProSight intends to list its common

Continue reading “ProSight Global files to go public”

VC-backed Karuna goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Karuna Therapeutics, a biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, has raised $89.2 million for its IPO after pricing its over 5.5 million shares at $16 per share. The stock began trading June 28, 2019 on the NASDAQ under the ticker symbol “KRTX.” Goldman Sachs and Citigroup are the lead underwriters. Karuna’s pre-IPO backers included ARCH Venture Partners, Fidelity Management & Research Co, Eventide Asset Management, Pivotal bioVenture Partners, Partner Fund Management, Wellcome Trust, Sands Capital and Alexandria Venture Investments.

PRESS RELEASE

BOSTON–(BUSINESS WIRE)–$KRTX–Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. In addition, Karuna has granted the underwriters a 30-day option to

Continue reading “VC-backed Karuna goes public”

VC-backed Adaptive goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Seattle-based Adaptive, a biotech company, has raised $300 million for its IPO after pricing its 15 million shares at $20 per share. The stock began trading June 27, 2019 on the NASDAQ under the ticker symbol “ADPT.” Goldman Sachs, J.P. Morgan and BofA Merrill Lynch are the lead underwriters. Adaptive’s pre-IPO backers include Viking Global Matrix Capital Management Celgene, Foresite Capital and Alexandria Venture Investments.

PRESS RELEASE

SEATTLE, June 26, 2019 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient lives, today announced the pricing of its initial public offering of 15,000,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. The gross proceeds of the offering, before deducting underwriting discounts and commissions

Continue reading “VC-backed Adaptive goes public”

Biopharma firm Morphic debuts IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Waltham, Massachusetts-based Morphic, a biopharmaceutical company, has raised about $90 million for its IPO after pricing its 6 million shares at $15 per share. The stock began trading June 27, 2019 on the NASDAQ under the ticker symbol “MORF.” Jefferies LLC, Cowen and Company, LLC, BMO Capital Markets Corp. and Wells Fargo Securities LLC are the underwriters. Morphic’s pre-IPO backers included Omega Funds, Novo Holdings, Invus and EcoR1 Capital.

PRESS RELEASE

WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per share. The shares are expected to begin trading on The Nasdaq Global Market on June 27, 2019 under the symbol “MORF.” The offering is expected to close on July 1, 2019,

Continue reading “Biopharma firm Morphic debuts IPO”

PE-backed Cambium goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Cambium, a provider of wireless broadband networking infrastructure solutions, has debuted its IPO after pricing its 5.8 million shares at $12 per share. The stock began trading June 26, 2019 on the NASDAQ under the ticker symbol “CMBM.” JP Morgan Securities and Goldman Sachs are the lead underwriters. Cambium’s pre-IPO backer is Vector Capital.

PRESS RELEASE

ROLLING MEADOWS, Ill., June 25, 2019 (GLOBE NEWSWIRE) — Cambium Networks Corporation (“Cambium”), a provider of wireless broadband networking infrastructure solutions, today announced the pricing of its initial public offering of 5,800,000 ordinary shares at the initial public offering price of $12.00 per share.

The shares are expected to begin trading on The Nasdaq Global Market under the symbol “CMBM” on June 26, 2019, and the offering is expected to close on June 28, 2019, subject to customary closing conditions. In addition, Cambium has granted the underwriters a 30-day option

Continue reading “PE-backed Cambium goes public”

VC-backed Phreesia files to go public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




New York-based Phreesia, a healthcare software company, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading the stock on the New York Stock Exchange under the ticker symbol “PHR.” J.P. Morgan, Wells Fargo Securities and William Blair are the lead underwriters. Phreesia’s backers include LLR Partners, HLM Venture Partners, Polaris Partners, Ascension Ventures, Echo Health Venture and Blue Cross Blue Shield Venture Partners.

PRESS RELEASE

NEW YORK, June 24, 2019 /PRNewswire/ — Phreesia announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock.

The number of shares to be offered and the price range for the proposed offering have not yet been determined. The

Continue reading “VC-backed Phreesia files to go public”

VC-backed Akero Therapeutics debuts IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Akero Therapeutics Inc, a biotech firm, has raised about $92 million for its IPO after pricing its 5.75 million shares at $16 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “AKRO.” J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C. are the lead underwriters. Akero’s pre-IPO investors included Janus Henderson Investors, Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, LifeSci Venture Partners, Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.

PRESS RELEASE

SAN FRANCISCO, June 19, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the pricing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $16.00 per

Continue reading “VC-backed Akero Therapeutics debuts IPO”

Prevail Therapeutics begins trading on NASDAQ


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




New York City-based Prevail Therapeutics, a gene therapy company, has gone public after pricing its over 7.3 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “PRVL.” Morgan Stanley, BofA Merrill Lynch and Cowen are the lead underwriters. Prevail’s pre-IPO backers included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners LP, Boxer Capital LLC, Adage Capital Management LP and Alexandria Venture Investments.

PRESS RELEASE

NEW YORK–(BUSINESS WIRE)–Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share. In addition, Prevail has granted the underwriters a 30-day option to purchase up to an additional 1,102,950 shares of

Continue reading “Prevail Therapeutics begins trading on NASDAQ”

VC-backed Personalis unveils IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Personalis Inc, a provider of advanced genomics solutions for cancer, has debuted its IPO after pricing its nearly 8 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “PSNL.” Morgan Stanley, BofA Merrill Lynch and Cowen are the lead underwriters. Personalis’ pre-IPO backers included Lightspeed Venture Partners, Abingworth and Mohr Davidow Ventures.

PRESS RELEASE

MENLO PARK, Calif.–(BUSINESS WIRE)–
Personalis, Inc., a leader in advanced genomics for cancer, today announced the pricing of its initial public offering of 7,921,500 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Personalis. In addition, Personalis has granted the underwriters a 30-day option to purchase up to an additional 1,188,225 shares of common stock from Personalis at the public offering price less underwriting

™

Continue reading “VC-backed Personalis unveils IPO”

Biopharma firm Atreca goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Redwood City, California-based Atreca Inc, a biopharmaceutical company, has raised about $113.8 million for its IPO after pricing its 7.35 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “BCEL.” Cowen, Evercore ISI and Stifel are the lead underwriters. Atreca’s pre-IPO backers included Wellington Management Company LLC, Cormorant Asset Management, Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.

PRESS RELEASE

REDWOOD CITY, Calif., June 19, 2019 (GLOBE NEWSWIRE) — Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a price to the public of $17.00 per share.

Continue reading “Biopharma firm Atreca goes public”

VC-backed Fiverr goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Fiverr International, an online marketplace for freelancers, has debuted its IPO after raising over 5.2 million shares at $21 per share. The stock began trading June 13, 2019 on the New York Stock Exchange under the ticker symbol “FVRR.” J.P. Morgan Securities LLC and Citigroup Global Markets Inc are the lead underwriters. Fiverr’s pre-IPO backers included Square Peg Capital, Bessemer Venture Partners, Accel and Qumra Capital.

PRESS RELEASE

NEW YORK–(BUSINESS WIRE)–
Fiverr International Ltd. (“Fiverr”), announced today the pricing of its initial public offering of 5,263,158 ordinary shares at a public offering price of $21.00 per share. The underwriters of the offering will also have a 30-day option to purchase up to an additional 789,473 ordinary shares from Fiverr at the initial public offering price. The shares are expected to begin trading on the New York Stock Exchange on June 13, 2019 under the ticker

Continue reading “VC-backed Fiverr goes public”

VC-backed Fiverr goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Fiverr International, an online marketplace for freelancers, has debuted its IPO after pricing its over 5.2 million shares at $21 per share. The stock began trading June 13, 2019 on the New York Stock Exchange under the ticker symbol “FVRR.” J.P. Morgan Securities LLC and Citigroup Global Markets Inc are the lead underwriters. Fiverr’s pre-IPO backers included Square Peg Capital, Bessemer Venture Partners, Accel and Qumra Capital.

PRESS RELEASE

NEW YORK–(BUSINESS WIRE)–
Fiverr International Ltd. (“Fiverr”), announced today the pricing of its initial public offering of 5,263,158 ordinary shares at a public offering price of $21.00 per share. The underwriters of the offering will also have a 30-day option to purchase up to an additional 789,473 ordinary shares from Fiverr at the initial public offering price. The shares are expected to begin trading on the New York Stock Exchange on June 13, 2019 under the

Continue reading “VC-backed Fiverr goes public”